Primer Peritoneal Kanserler
Özet
Primer peritoneal kanserler (PPK), nadir görülen ve kötü prognoza sahip intraabdominal tümörlerdir. Over kanserlerine benzerlik gösterseler de farklı klinik özelliklere sahip bir tümör grubudur. Çoğunlukla ileri evrelerde tanı konulur ve karın ağrısı, kilo kaybı, bulantı, kusma, asit gibi şikayetlerle kendini gösterir. Tanı için öykü, fizik muayene, görüntüleme yöntemleri ve biyopsi kullanılır. PPK’lerin tedavisi, cerrahi, kemoterapi ve hedefli tedavilerle yapılırken, hastalığın evresi, tümör tipi ve hastanın durumu tedavi yaklaşımını belirler. Papiller mezotelyoma, multikistik mezotelyoma, seröz karsinom, leiomyosarkomlar ve desmoplastik küçük yuvarlak hücreli tümörler gibi alt gruplara ayrılan PPK’ler, genellikle tedaviye dirençli olup, erken tanı ve multidisipliner yaklaşımlar prognozu iyileştirebilir. Her bir PPK türü için takip, hastalığın nüks etme riskine göre belirlenilir. Erken nükslerin tespiti ve tedaviye bağlı komplikasyonların önlenmesi için düzenli takipler önemlidir.
Primary peritoneal cancers (PPC) are rare intraabdominal tumors with a poor prognosis. Although they resemble ovarian cancers, they have distinct clinical characteristics. Diagnosis is often made at advanced stages, with symptoms such as abdominal pain, weight loss, nausea, vomiting, and ascites. Diagnosis involves patient history, physical examination, imaging techniques, and biopsy. Treatment of PPC involves surgery, chemotherapy, and targeted therapies, with the treatment approach determined by the disease stage, tumor type, and patient's condition. PPCs, which are divided into subgroups such as papillary mesothelioma, multicystic mesothelioma, serous carcinoma, leiomyosarcomas, and desmoplastic small round cell tumors, are generally resistant to treatment. Early diagnosis and multidisciplinary approaches can improve prognosis. Follow-up for each type of PPC is determined according to the risk of recurrence of the disease. Regular follow-up is important for the detection of early recurrences and the prevention of treatment-related complications.
Referanslar
Cotte E, Passot G, Isaac S, Gilly FN, Glehen O. [Malignant primary peritoneal tumors]. Presse Med. 2009;38(12):1814-22.
Miguez Gonzalez J, Calaf Forn F, Pelegri Martinez L, Lozano Arranz P, Oliveira Caiafa R, Catala Forteza J, et al. Primary and secondary tumors of the peritoneum: key imaging features and differential diagnosis with surgical and pathological correlation. Insights Imaging. 2023;14(1):115.
Gan J, Herzog J, Smith DA, Vos D, Kikano E, Tirumani SH, et al. Primary peritoneal serous carcinoma: a primer for radiologists. Clin Imaging. 2022;83:56-64.
Deraco M, Kusamura S, Baratti D, Casali P, Zaffaroni N. [Peritoneal mesothelioma: results of a complicated and aggressive procedure incorporating peritonectomy and intraperitoneal hyperthermic chemotherapy, and prospects derived from bench-to-bedside research]. Tumori. 2003;89(4 Suppl):56-7.
Liang YF, Zheng GQ, Chen YF, Song H, Yin WJ, Zhang L. CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. J Gastroenterol Hepatol. 2016;31(4):709-15.
Anwar A, Kasi A. Peritoneal Cancer. StatPearls. Treasure Island (FL)2024.
Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics. 2008;28(2):583-607; quiz 21-2.
Gemba K, Fujimoto N, Aoe K, Kato K, Takeshima Y, Inai K, et al. Treatment and survival analyses of malignant mesothelioma in Japan. Acta Oncol. 2013;52(4):803-8.
Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5(11):236.
de Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori. 2005;91(1):1-5.
Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007;9(2):32.
Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89(3):269-73.
Pickhardt PJ, Bhalla S. Primary neoplasms of peritoneal and sub-peritoneal origin: CT findings. Radiographics. 2005;25(4):983-95.
Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591-603.
Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg. 1999;384(6):576-87.
Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, et al. Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma. Hepatogastroenterology. 2004;51(58):1073-83.
Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer. 1987;59(11):1882-6.
Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228-35.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86.
Noiret B, Renaud F, Piessen G, Eveno C. Multicystic peritoneal mesothelioma: a systematic review of the literature. Pleura Peritoneum. 2019;4(3):20190024.
Mino JS, Monteiro R, Pigalarga R, Varghese S, Guisto L, Rezac C. Diffuse malignant epithelioid mesothelioma in a background of benign multicystic peritoneal mesothelioma: a case report and review of the literature. BMJ Case Rep. 2014;2014.
Zhang CH, Yu JW, Luo M. Multicystic peritoneal mesothelioma: A short review. Curr Probl Cancer. 2017;41(5):340-8.
Jouvin I, Dohan A, Gergi P, Pocard M. Intra-abdominal benign multicystic peritoneal mesothelioma. J Visc Surg. 2014;151(2):155-7.
Bell DA, Scully RE. Benign and borderline serous lesions of the peritoneum in women. Pathol Annu. 1989;24 Pt 2:1-21.
Sugarbaker P, Yan T, Zappa L, Haveric N, Brun E. Thin-walled cysts as a pathognomonic CT finding in cystic mesothelioma. Tumori. 2008;94(1):14-8.
Mehta V, Chowdhary V, Sharma R, Golia Pernicka JS. Imaging appearance of benign multicystic peritoneal mesothelioma: a case report and review of the literature. Clin Imaging. 2017;42:133-7.
van Ruth S, Bronkhorst MW, van Coevorden F, Zoetmulder FA. Peritoneal benign cystic mesothelioma: a case report and review of the literature. Eur J Surg Oncol. 2002;28(2):192-5.
Baratti D, Vaira M, Kusamura S, D'Amico S, Balestra MR, Cioppa T, et al. Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Eur J Surg Oncol. 2010;36(11):1047-53.
Letterie GS, Yon JL. The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma. Gynecol Oncol. 1998;70(1):131-3.
Letterie GS, Yon JL. Use of a long-acting GnRH agonist for benign cystic mesothelioma. Obstet Gynecol. 1995;85(5 Pt 2):901-3.
Ross MJ, Welch WR, Scully RE. Multilocular peritoneal inclusion cysts (so-called cystic mesotheliomas). Cancer. 1989;64(6):1336-46.
Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(1):132-9.
Rothacker D, Mobius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. Int J Gynecol Pathol. 1995;14(4):310-8.
Yuan J, He L, Han B, Li Y. Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review. World J Surg Oncol. 2017;15(1):76.
Resta L, Maiorano E, Zito FA, Faggiano F, Loizzi P, Ferreri R, et al. Multifocal extraovarian serous carcinoma. A histochemical and immunohistochemical study. Eur J Gynaecol Oncol. 1988;9(6):474-8.
Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol. 2010;75(1):27-42.
Mills SE, Andersen WA, Fechner RE, Austin MB. Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma. Am J Surg Pathol. 1988;12(11):827-34.
Rassy E, Assi T, Boussios S, Kattan J, Smith-Gagen J, Pavlidis N. Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. Ann Transl Med. 2020;8(24):1709.
Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol. 2015;136(1):25-9.
Chao KC, Chen YJ, Juang CM, Lau HY, Wen KC, Sung PL, et al. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan. Taiwan J Obstet Gynecol. 2013;52(1):81-4.
Sun JH, Ji ZH, Peng KW, Wu HT, Zhang Q, Yonemura Y, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study. Int J Hyperthermia. 2016;32(3):289-97.
Cautero N, De Luca S, Vecchi A, Garelli P, Nicolini D, Martorelli G, et al. Peritoneal leiomyosarcoma in a kidney transplant patient: a case report. Transplant Proc. 2007;39(6):2038-9.
Deyrup AT, Folpe A, Inwards C. Bone & Soft Tissue Pathology. Saunders/Elsevier Philadelphia; 2010.
Bharti J, Dey B, Desai P, Gupta R, Khurana N, Gandhi G. Primary Leiomyosarcoma of Peritoneal Cavity. Rare tumors. 2014;6:5165.
Montgomery E, Aaron AD. Clinical pathology of soft-tissue tumors. (No Title). 2001.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016;34(8):786-93.
Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res. 2016;6:9.
O'Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116(3):424-9.
Thanopoulou E, Thway K, Khabra K, Judson I. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res. 2014;4:5.
D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416-26.
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-74.
Dorsey BV, Benjamin LE, Rauscher F, 3rd, Klencke B, Venook AP, Warren RS, et al. Intra-abdominal desmoplastic small round-cell tumor: expansion of the pathologic profile. Mod Pathol. 1996;9(6):703-9.
Tang Y, Song H, Bao Y, Zhi Y. Multimodal treatment of abdominal and pelvic desmoplastic small round cell tumor with relative good prognosis. Int J Surg. 2015;16(Pt A):49-54.
Zhang GM, Zhu Y, Gan HL, Ye DW. Testicular desmoplastic small round cell tumor: a case report and review of literature. World J Surg Oncol. 2014;12:227.
Honore C, Amroun K, Vilcot L, Mir O, Domont J, Terrier P, et al. Abdominal desmoplastic small round cell tumor: multimodal treatment combining chemotherapy, surgery, and radiotherapy is the best option. Ann Surg Oncol. 2015;22(4):1073-9.
Thuret R, Renaudin K, Leclere J, Battisti S, Bouchot O, Theodore C. Uncommon malignancies: case 3. Paratesticular desmoplastic small round-cell tumor. J Clin Oncol. 2005;23(25):6253-5.
Tateishi U, Hosono A, Makimoto A, Sakurada A, Terauchi T, Arai Y, et al. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas. J Pediatr Hematol Oncol. 2007;29(9):608-12.
Tsoukalas N, Kiakou M, Nakos G, Tolia M, Galanopoulos M, Tsapakidis K, et al. Desmoplastic small round-cell tumour of the peritoneal cavity: case report and literature review. Ann R Coll Surg Engl. 2020;102(4):e77-e81.
Lippe P, Berardi R, Cappelletti C, Massacesi C, Mattioli R, Latini L, et al. Desmoplastic small round cell tumour: a description of two cases and review of the literature. Oncology. 2003;64(1):14-7.
Bisogno G, Ferrari A, Rosolen A, Alaggio R, Scarzello G, Garaventa A, et al. Sequential intensified chemotherapy with stem cell rescue for children and adolescents with desmoplastic small round-cell tumor. Bone Marrow Transplant. 2010;45(5):907-11.
Alexander HR, Jr., Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153(6):779-86.
Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D, et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer. 2016;65:69-79.
Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140-8.
NCCN Guidelines Version 3.2024 Ovarian Cancer. [Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Access date: 01.01.2025.
UpToDate [Available from: https://www.uptodate.com/contents/local-treatment-for-gastrointestinal-stromal-tumors-leiomyomas-and-leiomyosarcomas-of-the-gastrointestinal-tract?search=Leiomyosarcoma%20follow%20up&source=search_result&selectedTitle=2%7E86&usage_type=default&display_rank=2#H10. Access date: 01.01.2025.
NCCN Guidelines Version 4.2024 Soft Tissue Sarcoma. Available from: www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Access date: 02.01.2025.
